Overview: JAK2 Exon 12 Mutation TestIntroduction: The JAK2 Exon 12 Mutation Test detects JAK2 exon 12 mutations to diagnose myeloproliferative disorders like polycythemia vera, causing fatigue or clotting. Aligned with 2023 WHO guidelines, it uses PCR for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected myeloproliferative neoplasms.
Other Names: JAK2 Exon 12 PCR Assay, Polycythemia Vera Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: JAK2 exon 12 testing began in the 2000s with myeloproliferative disorder research. PCR-based methods improved diagnostic precision.
Purpose: Detects JAK2 exon 12 mutation to diagnose myeloproliferative disorders, guides treatment, and evaluates patients with fatigue or clotting.
Test Parameters: 1. JAK2 Exon 12 Mutation
Pretest Condition: No fasting required. Collect whole blood, bone marrow, or saliva. Report history of fatigue, clotting, or erythrocytosis.
Specimen: Whole Blood (EDTA, 2-5 mL), Bone Marrow (EDTA, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document fatigue, clotting, erythrocytosis, or family history of myeloproliferative disorders. Include current medications, especially hydroxyurea.
Consent: Written consent required, detailing the tests purpose, disorder implications, and risks of blood or bone marrow collection.
Procedural Considerations: Uses PCR to detect JAK2 exon 12 mutations in whole blood, bone marrow, or saliva. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for polycythemia vera diagnosis.
Factors Affecting Result Accuracy: Improper sample storage or contamination can affect results. Low DNA yield may reduce sensitivity.
Clinical Significance: Positive JAK2 exon 12 mutation confirms polycythemia vera or related disorders, guiding phlebotomy or targeted therapy. Negative results may require further genetic testing.
Specialist Consultation: Consult a hematologist for result interpretation and treatment planning.
Additional Supporting Tests: JAK2 V617F PCR, CALR mutation testing, or bone marrow biopsy to confirm myeloproliferative disorder diagnosis.
Test Limitations: Not specific to one disorder; clinical correlation is needed. Rare mutations may not be detected.
References: WHO Hematopathology Guidelines, 2023; Blood, Tefferi A, 2022.
